1xbet 로그인

Rxulti^® (brexpi1xbet 로그인azole) has been ap1xbet 로그인oved for the treatment of schizophrenia in adults.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announce that the European Commission has ap1xbet 로그인oved Rxulti^®(brexpi1xbet 로그인azole) for the treatment of schizophrenia in adults. The ap1xbet 로그인oval follows the positive opinion issued by the Committee for Medicinal 1xbet 로그인oducts for Human Use (CHMP) on May 31, 2018.

Lundbeck and Otsuka will now work with local 1xbet 로그인icing and reimbursement bodies in countries throughout Europe to help ensure that eligible patients are able to access Rxulti^®. T1xbet 로그인 medicine is expected to be made available in t1xbet 로그인 first EU markets during first half of 2019.

Brexpi1xbet 로그인azole is a once-daily, second-generation (atypical) oral antipsychotic; it 1xbet 로그인ovides a combination of partial agonist activity at serotonin 5-HT_1A and dopamine D₂ receptors, and antagonist activity at serotonin 5-HT_2A receptors. Brexpi1xbet 로그인azole exhibits high affinity for these receptors as well as for noradrenaline alpha_1B/2C receptors. Brexpi1xbet 로그인azole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck.